Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Relmada Therapeutics (RLMD) EPS (Basic) (2016 - 2026)

Relmada Therapeutics has reported EPS (Basic) over the past 3 years, most recently at -$0.0 for Q1 2014.

  • Quarterly EPS (Basic) rose 37.87% to -$0.0 in Q1 2014 from the year-ago period, while the trailing twelve-month figure was -$0.0 through Feb 2014, down 25.62% year-over-year, with the annual reading at -$1.45 for FY2025, 45.28% up from the prior year.
  • EPS (Basic) was -$0.0 for Q1 2014 at Relmada Therapeutics, up from -$0.0 in the prior quarter.
  • Over five years, EPS (Basic) peaked at -$0.0 in Q1 2014 and troughed at -$0.0 in Q2 2013.
  • The 3-year median for EPS (Basic) is -$0.0 (2012), against an average of -$0.0.
  • Year-over-year, EPS (Basic) tumbled 371.33% in 2013 and then surged 37.87% in 2014.
  • A 3-year view of EPS (Basic) shows it stood at -$0.0 in 2012, then plummeted by 31.4% to -$0.0 in 2013, then soared by 78.27% to -$0.0 in 2014.
  • Per Business Quant, the three most recent readings for RLMD's EPS (Basic) are -$0.0 (Q1 2014), -$0.0 (Q4 2013), and -$0.0 (Q2 2013).